Rhythm Pharmaceuticals, Inc.: Obesity trials
The registry lists 19 Obesity studies with Rhythm Pharmaceuticals, Inc. as lead sponsor. 0 are open to participants now and 10 have results posted.
Phase 1 4Phase 2 8Phase 3 7No phase 3(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R PathwayCompletedNCT05093634Phase 3Results posted
- Setmelanotide in Pediatric Participants With Rare Genetic Diseases of ObesityCompletedNCT04966741Phase 3Results posted
- DAYBREAK: A Study of Setmelanotide in Participants With Specific Gene Variants in the Melanocortin-4 Receptor (MC4R) PathwayCompletedNCT04963231Phase 2Results posted
- Setmelanotide (RM-493), Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and Alström Syndrome (AS) Participants With Moderate to Severe ObesityCompletedNCT03746522Phase 3Results posted
- Long Term Extension Trial of SetmelanotideCompletedNCT03651765Phase 2/3Results posted
- Setmelanotide for the Treatment of Leptin Receptor (LEPR) Deficiency ObesityCompletedNCT03287960Phase 3Results posted
- Setmelanotide Phase 2 Treatment Trial in Participants With Rare Genetic Disorders of ObesityCompletedNCT03013543Phase 2Results posted
- Setmelanotide for the Treatment of Early-Onset Pro-Opiomelanocortin (POMC) Deficiency ObesityCompletedNCT02896192Phase 3Results posted
- Phase 2 Trial to Evaluate Safety and Efficacy of Setmelanotide (RM-493) in Obese Participants With Prader-Willi SyndromeCompletedNCT02311673Phase 2Results posted
- Phase 1b/2a Study to Evaluate Safety and Efficacy of Setmelanotide in Obese PatientsCompletedNCT02041195Phase 1/2Results posted
- A Study of Setmelanotide in Patients With Prader-Willi SyndromeActive, not recruitingNCT06772597Phase 2
- Open-Label Extension Study of SetmelanotideCompletedNCT06596135Phase 3
- A Study of RM-718 in Healthy Subjects and Patients With MC4R Pathway ImpairmentActive, not recruitingNCT06239116Phase 1/2
- An Expanded Access Protocol for Setmelanotide for Treatment of Bardet-Biedl Syndrome (BBS)Approved for marketingNCT05183802
- An Observational,Prospective Natural History Study of Early-Onset Extreme Obesity Due to Bi-Allelic Loss-of-Function Mutations in the POMC, PCSK1 or LEPR GenesCompletedNCT03621007
- The TEMPO (Tracing the Effect of the MC4 Pathway in Obesity) RegistryCompletedNCT03479437
- Setmelanotide in a Single Patient With Partial LipodystrophyCompletedNCT03262610Phase 2
- Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RM-493 Administered to Healthy, Obese, Non-diabetic VolunteersCompletedNCT02431442Phase 1
- Effects of RM-493 on Energy Expenditure in Obese IndividualsCompletedNCT01867437Phase 1